Abstract:Although breakthroughs in cancer treatment have been achieved, immunotherapy yields only modest benefits in most patients. There is still a gap in clarifying the immune evasiveness and immune-resistance mechanisms. Identifying other candidate targets for cancer immunotherapy is therefore a clear unmet clinical need. The complement system, a pillar of innate immunity, has recently entered the limelight due to its immunoregulatory functions in the tumor microenvironment (TME). In particular, gC1qR, a receptor for globular heads of C1q, serves as a promising new target and has attracted more attention. gC1qR, also named P32/C1qBP/HABP1, is a multifunctional protein that is overexpressed in various cancers and holds prognostic value. It regulates the tumorigenic, progression and metastatic properties of tumor cells through several downstream signaling pathways, including the Wnt/β-catenin, PKC-NF-κB and Akt/PKB pathways. A few preclinical experiments conducted through gC1qR interventions, such as monoclonal antibody, chimeric antigen receptor T-cell (CAR-T) therapy, and tumor vaccination, have shown encouraging results in anticancer activity. The efficacy may rely on the regulatory role on the TME, induction of tumor cells apoptosis and antiangiogenic activity. Nevertheless, the current understanding of the relationship between cancer immunotherapy and gC1qR remains elusive and often contradictory, posing both opportunities and challenges for therapeutic translation in the clinic. In this review, we focus on the current understanding of gC1qR function in cancer immunology and highlight the vital roles in regulating the TME. We also examines the rationale behind targeting gC1qR and discusses the potential for translating into clinical practice.

GPCRs: emerging targets for novel T cell immune checkpoint therapy

Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies

Tumor Immune Checkpoints and Their Associated Inhibitors

G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy

The Advancement of Pathway on G Protein-coupled Receptors(GPCRs) Target to Cancer

Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy.

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

G Protein–Coupled Receptor (GPCR) Expression in Native Cells: “Novel” endoGPCRs as Physiologic Regulators and Therapeutic Targets

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Immune checkpoint: The novel target for antitumor therapy

GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment

gC1qR: A New Target for Cancer Immunotherapy

An Insight into GPCR and G-Proteins as Cancer Drivers

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

GPCRs as targets for flavonoids in cancer cells: new options for intervention